The Asia Pacific GLP-1 analogues market is expected to register the highest CAGR during the forecast period due to an increasing proportion of the aging population
What specific cardiovascular conditions qualify for potential Wegovy coverage
GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and a growing pipeline of new entrants are being prescribed to tens of millions of Americans for weight loss and diabetes management, and they are fundamentally altering how, when, and how much people eat
This has led to increased adoption of global market in treating obesity, propelling its market presence to notable levels
The flexibility in dosing allows for better management of adverse effects, ensuring a safer treatment protocol